PRTAProthena Corp. Plc
9.450USDMkt Cap: 485.13M $P/E: —3d ago
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab…
Industry Peers
BiotechnologyKey Statistics
Company
Market Cap485.13M $
Enterprise Value182.37M $
Revenue (TTM)54.53M $
Gross Profit-10.42M $
Net Income (TTM)-244.09M $
Revenue/Share1.022 USD
Last Price9.450 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees67
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINIE00B91XRN20
Valuation
P/E (Trailing)—
P/E (Forward)-5.94
PEG—
EV/EBITDA-3.09
EV/Revenue3.34
P/S8.50
P/B1.63
EPS (TTM)-0.80
EPS (Forward)-1.52
52W Range
9.09084% of range9.520
52W High9.520 USD
52W Low9.090 USD
Profitability
Gross Margin-19.11%
Oper. Margin-1850.20%
EBITDA Margin-108.27%
Profit Margin-2520.57%
ROE-87.03%
ROA-74.69%
Growth
Revenue Growth-77.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-163.58M $
CapEx (TTM)138.00K $
FCF Margin-99.44%
FCF Yield-11.18%
Net Debt-281.20M $
Net Debt/EBITDA4.76
Balance Sheet
Debt/Equity0.03
Current Ratio25.05
Quick Ratio24.72
Book Value/Sh5.544 USD
Cash/Share5.614 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.5 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)21.40 USD
Upside (mean)+126.5%
Target Range8.000 USD – 36.00 USD
$8.000+126.5% to mean$36.00
# Analysts5
Ownership
Shares Out.51.34M
Float34.93M
Insiders22.11%
Institutions93.32%
Short Interest
Short Ratio15.0d
Short % Float19.17%
Short % Out.15.92%
Shares Short8.17M
Short (prev mo.)8.37M
Technical
SMA 508.893 (+6.3%)
SMA 2009.548 (-1.0%)
Beta-0.35
S&P 52W Chg21.00%
Avg Vol (30d)365.93K
Avg Vol (10d)402.01K
Technical Indicators
RSI (14)59.5
MACD0.0821
MACD Signal0.0053
MACD Hist.+0.0767
BB Upper9.521 USD
BB Middle8.795 USD
BB Lower8.069 USD
BB Width16.51%
ATR (14)0.4439 USD
Vol Ratio (20d)0.77x